Reduction of the Incidence of NAV in Neonatal Units (INBERNAV-Neo)
NCT07240038
Cross Infection, Disease Attributes
A Coruña, Spain
View Trial DetailsNCT Number: NCT07782372
This study aims to examine intensive care nurses' perceptions of leadership in quality culture for infection prevention and to investigate antimicrobial resistance indicators at the intensive care unit level. Healthcare-associated infections (HAIs) remain a major global patient safety problem and are associated with prolonged hospital stays, increased healthcare costs, and higher mortality. The increasing prevalence of antimicrobial resistance (AMR) further complicates infection prevention and patient care.
Intensive care units are particularly vulnerable to healthcare-associated infections and antimicrobial resistance because of the high frequency of invasive procedures, the vulnerability of critically ill patients, and the extensive use of broad-spectrum antibiotics. Nurses play a central role in infection prevention and antimicrobial stewardship because they are continuously involved in patient care. However, previous studies have reported a gap between nurses' knowledge of infection prevention and adherence to recommended practices in clinical settings. Organizational culture and leadership may contribute to this gap.
Most previous studies have focused on healthcare professionals' self-reported perceptions of infection prevention. However, limited evidence is available regarding the relationship between nurses' perceptions of leadership and quality culture and objective antimicrobial resistance indicators at the intensive care unit level. Therefore, this study will assess nurses' perceptions using the Leadership in Quality Culture for Infection Prevention (LCQ-IP) instrument and examine their relationship with retrospective microbiological data from the participating intensive care units, including antimicrobial resistance rates and resistance profiles. The findings may provide evidence on the role of organizational leadership and quality culture in infection prevention and antimicrobial resistance management in intensive care settings.
Trial opening soon.
Get NotifiedUp to 125 year
All sexes
Observational
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: Baseline
Leadership for a culture of quality in infection prevention will be assessed using the Turkish version of the Leading a Culture of Quality for Infection Prevention Scale. The scale consists of 16 items rated on a 5-point Likert scale. Total scores range from 16 to 80, with higher scores indicating a more positive perception of leadership for a culture of quality in infection prevention.
Time frame: The 1-year period preceding study enrollment
Contact information is provided by the study sponsor or research team.
Yeliz Sapulu Alakan
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07240038
Cross Infection, Disease Attributes
A Coruña, Spain
View Trial DetailsNCT06925620
Accuracy, Behavior
Kaohsiung City, Taiwan
View Trial DetailsNCT03749434
Cross Infection, Disease Attributes
Ann Arbor, Michigan, United States
View Trial DetailsNCT02244905
Cross Infection, Disease Attributes
View Trial Details